Investors

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

February 26, 2020
Summary Toggle Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (

December 18, 2019
Summary Toggle Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

December 10, 2019
Summary Toggle Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

December 10, 2019
Summary Toggle Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

November 11, 2019
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

November 06, 2019
Summary Toggle Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

August 07, 2019
Summary Toggle Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development

July 11, 2019
Summary Toggle Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors

July 02, 2019
Summary Toggle Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences

June 04, 2019
Summary Toggle Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights

May 08, 2019
Summary Toggle Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019

April 08, 2019
Summary Toggle Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis a

March 28, 2019
Summary Toggle Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

February 27, 2019
Summary Toggle Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018

November 12, 2018
Summary Toggle Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events

November 06, 2018
Summary Toggle Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements

August 07, 2018
Summary Toggle Madrigal Pharmaceuticals Prices Public Offering of Common Stock

June 06, 2018
Summary Toggle Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

June 05, 2018
Summary Toggle Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial

May 31, 2018
Summary Toggle Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements

May 08, 2018
Summary Toggle Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196

March 13, 2018
Summary Toggle Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

February 08, 2018
Summary Toggle Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018

January 30, 2018
Summary Toggle Madrigal Pharmaceuticals Prices Public Offering of Common Stock

December 18, 2017
Summary Toggle Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

December 18, 2017
Summary Toggle Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial

December 06, 2017
Summary Toggle Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results

November 09, 2017
Summary Toggle Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting

October 23, 2017
Summary Toggle Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

September 19, 2017
Summary Toggle Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results

August 10, 2017
Summary Toggle Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH

August 01, 2017
Summary Toggle Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering

June 21, 2017
Summary Toggle Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results

May 11, 2017
Summary Toggle Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196

April 03, 2017
Summary Toggle Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

February 23, 2017
Summary Toggle Madrigal Reports Third Quarter 2016 Financial Results

November 14, 2016
Summary Toggle Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)

October 20, 2016
Summary Toggle Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

September 19, 2016
Summary Toggle Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

July 22, 2016
Summary Toggle Synta Reports Third Quarter 2015 Financial Results

November 05, 2015
Summary Toggle Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

October 20, 2015
Summary Toggle Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

October 08, 2015
Summary Toggle Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

September 09, 2015
Summary Toggle Synta Announces Presentations at the 16th Annual World Conference on Lung Cancer

September 08, 2015
Summary Toggle Synta to Participate in FBR Second Annual Healthcare Conference

September 02, 2015
Summary Toggle Synta Reports Second Quarter 2015 Financial Results

August 06, 2015
Summary Toggle Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015

July 30, 2015
Summary Toggle Synta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition and Immune Checkpoint Blockade for Cancer Therapy

June 23, 2015
Summary Toggle Synta to Participate in Upcoming Investor Conferences

June 16, 2015
Summary Toggle Synta Announces Ganetespib Program Updates

June 02, 2015
Summary Toggle Synta Announces Presentations at the 2015 ASCO Annual Meeting

May 28, 2015
Summary Toggle Synta to Present at the Jefferies 2015 Global Healthcare Conference

May 27, 2015
Summary Toggle Synta Reports First Quarter 2015 Financial Results

May 07, 2015
Summary Toggle Synta to Host Conference Call and Webcast of First Quarter 2015 Financial Results on May 7, 2015

April 30, 2015
Summary Toggle Synta Announces Chen Schor Named President, Chief Executive Officer and Director

April 27, 2015
Summary Toggle Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer Research

April 16, 2015
Summary Toggle Synta Pharmaceuticals Closes Public Offering of Common Stock

April 06, 2015
Summary Toggle Synta Pharmaceuticals Prices Public Offering of Common Stock

March 31, 2015
Summary Toggle Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 30, 2015
Summary Toggle Synta Reports Fourth Quarter and Year-End 2014 Financial Results

March 12, 2015
Summary Toggle Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2014 Financial Results on March 12, 2015

February 26, 2015
Summary Toggle Synta to Present at Upcoming Conferences

February 25, 2015
Summary Toggle Synta Outlines New Corporate Strategy

February 05, 2015
Summary Toggle Synta to Present at the 17th Annual BIO CEO & Investor Conference

February 03, 2015
Summary Toggle Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium

December 12, 2014
Summary Toggle Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer

December 10, 2014
Summary Toggle Synta Strengthens Management Team with Two Executive Appointments

December 04, 2014
Summary Toggle Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR Symposium

November 19, 2014
Summary Toggle Synta to Present at the Stifel 2014 Healthcare Conference

November 12, 2014
Summary Toggle Synta Reports Third Quarter Financial Results and Provides Corporate Update

November 06, 2014
Summary Toggle Synta Announces FDA’s Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib

November 05, 2014
Summary Toggle Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer

October 29, 2014
Summary Toggle Synta to Host Conference Call and Webcast of Third Quarter 2014 Financial Results on November 6, 2014

October 27, 2014
Summary Toggle Synta Reports Inducement Grant to New Chief Executive Officer

September 04, 2014
Summary Toggle Synta Names Anne Whitaker Chief Executive Officer

August 06, 2014
Summary Toggle Synta Reports Second Quarter Financial Results and Provides Corporate Update

August 06, 2014
Summary Toggle Synta to Host Conference Call and Webcast of Second Quarter 2014 Financial Results on August 6, 2014

July 30, 2014
Summary Toggle Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS

July 21, 2014
Summary Toggle Synta to Present at the 9th Annual JMP Securities Healthcare Conference

June 19, 2014
Summary Toggle Synta to Present at the Jefferies 2014 Global Healthcare Conference

May 29, 2014
Summary Toggle Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting

May 28, 2014
Summary Toggle Synta Reports First Quarter 2014 Financial Results and Provides Corporate Update

May 08, 2014
Summary Toggle Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

May 08, 2014
Summary Toggle Synta to Host Conference Call and Webcast of First Quarter 2014 Financial Results on May 8, 2014

April 29, 2014
Summary Toggle Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner

April 14, 2014
Summary Toggle Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research

April 07, 2014
Summary Toggle Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference

March 20, 2014
Summary Toggle Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update

March 11, 2014
Summary Toggle Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer

March 11, 2014
Summary Toggle Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director

March 03, 2014
Summary Toggle Synta to Present on Hsp90-inhibitor Drug Conjugate Platform at the 12th International Congress on Targeted Anticancer Therapies

February 28, 2014
Summary Toggle Synta to Present at Upcoming Conferences

February 27, 2014
Summary Toggle Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2013 Financial Results on March 11, 2014

February 26, 2014
Summary Toggle Synta Reports on Progress with Lead HDC Compounds at IASLC Conference

February 24, 2014
Summary Toggle Synta Announces Upcoming Oral Presentations on Hsp90-Inhibitor Drug Conjugate (HDC) Platform

February 18, 2014
Summary Toggle Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer

January 09, 2014
Summary Toggle Synta Announces Initiation of Three Multicenter, Randomized Phase II/III Trials of Ganetespib in Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

January 09, 2014
Summary Toggle Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development

December 20, 2013
Summary Toggle Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 2013 San Antonio Breast Cancer Symposium

December 12, 2013
Summary Toggle Synta Announces Publications Demonstrating Ganetespib Activity in Triple-Negative Breast Cancer Models

November 21, 2013
Summary Toggle Synta Pharmaceuticals Closes Public Offering of Common Stock

November 18, 2013
Summary Toggle Synta Pharmaceuticals Prices Public Offering of Common Stock

November 13, 2013
Summary Toggle Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

November 12, 2013
Summary Toggle Synta Provides Clinical Updates and Reports Third Quarter 2013 Financial Results

November 04, 2013
Summary Toggle Synta Announces Publication of First Patent Application Covering its Hsp90-inhibitor Drug Conjugate (HDC) Platform

October 31, 2013
Summary Toggle Synta to Host Conference Call and Webcast of Third Quarter 2013 Financial Results on November 4, 2013

October 29, 2013
Summary Toggle Synta Announces Positive One-Year Follow-up Results for the GALAXY-1 Trial of Ganetespib in NSCLC at the 2013 World Conference on Lung Cancer

October 26, 2013
Summary Toggle Synta Announces Upcoming Presentations at the 15th World Conference on Lung Cancer

October 23, 2013
Summary Toggle Synta Announces Presentation of Ganetespib Results at the 2013 European Cancer Congress

September 28, 2013
Summary Toggle Synta to Host Investor Reception and Webcast at the 2013 European Cancer Congress

September 25, 2013
Summary Toggle Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcinoma

September 12, 2013
Summary Toggle Synta Announces Presentations at the 2013 European Cancer Congress

September 12, 2013
Summary Toggle Synta Announces Launch of Proprietary Small Molecule Hsp90-inhibitor Drug Conjugate Platform

September 10, 2013
Summary Toggle Synta to Present at the Stifel 2013 Healthcare Conference

September 04, 2013
Summary Toggle Interim Results of the GALAXY-1 Trial to be Presented at Best of ASCO

August 07, 2013
Summary Toggle Synta Provides Clinical Updates and Reports Second Quarter 2013 Financial Results

August 01, 2013
Summary Toggle Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial

July 29, 2013
Summary Toggle Synta to Host Conference Call and Webcast of Second Quarter 2013 Financial Results on August 1, 2013

July 23, 2013
Summary Toggle Synta Announces Publication of Clinical and Non-Clinical Results Demonstrating Unique Anti-angiogenic Effects of Ganetespib

July 17, 2013
Summary Toggle Synta to Present at the 8th Annual JMP Securities Healthcare Conference

June 27, 2013
Summary Toggle Synta to Present at the Jefferies 2013 Global Healthcare Conference

June 04, 2013
Summary Toggle Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer

June 03, 2013
Summary Toggle Synta to Host Investor Meeting and Webcast at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2013
Summary Toggle Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting

May 15, 2013
Summary Toggle Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results

April 30, 2013
Summary Toggle Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer

April 22, 2013
Summary Toggle Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013

April 16, 2013
Summary Toggle Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research

April 05, 2013
Summary Toggle Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results

March 14, 2013
Summary Toggle Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development

March 13, 2013
Summary Toggle Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013

February 25, 2013
Summary Toggle Synta to Present at Upcoming Conferences

February 11, 2013
Summary Toggle Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering

December 13, 2012
Summary Toggle Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock

December 12, 2012
Summary Toggle Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST

November 27, 2012
Summary Toggle Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth Asia Pacific Lung Cancer Conference

November 26, 2012
Summary Toggle Synta to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

November 09, 2012
Summary Toggle Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium

November 07, 2012
Summary Toggle Synta Provides Clinical Update and Reports Third Quarter 2012 Financial Results

November 06, 2012
Summary Toggle Synta to Host Third Quarter 2012 Conference Call on November 6, 2012

October 24, 2012
Summary Toggle Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer

September 29, 2012
Summary Toggle Synta to Present Interim Results from the GALAXY™ Trial at ESMO 2012

September 18, 2012
Summary Toggle Synta to Present at Upcoming September Investor Conferences

September 06, 2012
Summary Toggle Synta to Present at the Stifel Nicolaus Healthcare Conference

August 29, 2012
Summary Toggle Synta to Present at Two Upcoming Investor Conferences

August 06, 2012
Summary Toggle Synta Provides Clinical Update and Reports Second Quarter 2012 Financial Results

August 02, 2012
Summary Toggle Synta Announces First Patients Treated in Two ALK Positive Lung Cancer Trials

August 02, 2012
Summary Toggle Synta Announces $25.8 Million Registered Direct Offering of Common Stock

July 26, 2012
Summary Toggle Synta to Host Second-Quarter 2012 Conference Call on August 2, 2012

July 19, 2012
Summary Toggle Synta to Present at the JMP Securities Healthcare Conference

July 05, 2012
Summary Toggle Synta Announces Results from Interim Analysis of the Randomized Phase 2b/3 GALAXY Trial Evaluating Ganetespib plus Docetaxel in Second-Line Non-Small Cell Lung Cancer

June 27, 2012
Summary Toggle Synta Announces Ganetespib Presentations at the Annual Meeting of the American Society for Clinical Oncology

June 04, 2012
Summary Toggle Synta to Present at the Jefferies 2012 Global Healthcare Conference

May 30, 2012
Summary Toggle Synta Announces Presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting

May 17, 2012
Summary Toggle Synta to Present at the Deutsche Bank 37th Annual Health Care Conference

May 03, 2012
Summary Toggle Synta Provides Clinical Update and Reports First Quarter 2012 Financial Results

May 03, 2012
Summary Toggle Synta to Host First-Quarter 2012 Conference Call on May 3, 2012

April 19, 2012
Summary Toggle Synta Announces Results Demonstrating Potent Ganetespib Activity across Broad Range of Crizotinib-Resistant ALK+ NSCLC models at the European Lung Cancer Conference

April 18, 2012
Summary Toggle Multiple Myeloma Research Consortium (MMRC) and Synta Pharmaceuticals Announce Initiation of Ganetespib Clinical Trial in Multiple Myeloma

April 10, 2012
Summary Toggle Synta Announces Results on Ganetespib Across a Range of Malignancies at the American Association for Cancer Research (AACR) Annual Meeting

April 04, 2012
Summary Toggle Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development

March 27, 2012
Summary Toggle Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs

March 12, 2012
Summary Toggle Synta to Present at the Roth Capital Partners 24th Annual OC Growth Stock Conference

March 06, 2012
Summary Toggle Synta to Present at the Cowen and Company 32nd Annual Health Care Conference

February 29, 2012
Summary Toggle Synta Announces Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting

February 29, 2012
Summary Toggle Synta Provides Clinical Update and Reports Fourth Quarter and Year End 2011 Financial Results

February 22, 2012
Summary Toggle Synta to Participate in Three Investor Conferences in February

February 16, 2012
Summary Toggle Synta to Host Fourth-Quarter and Year-End 2011 Conference Call on February 22, 2012

February 08, 2012
Summary Toggle Synta Pharmaceuticals Sells Additional 1,050,000 Shares of Common Stock

February 06, 2012
Summary Toggle Synta Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

February 06, 2012
Summary Toggle Synta Announces Publication of Results Showing Ganetespib Synergizes with Taxanes in Multiple Non-small Cell Lung Cancer Models

January 16, 2012
Summary Toggle Synta Pharmaceuticals and University of Toronto Researchers Elucidate Elesclomol Mechanism of Action Using Innovative Yeast-based Technology

January 12, 2012
Summary Toggle Synta Pharmaceuticals Closes Public Offering of Common Stock

January 11, 2012
Summary Toggle Ganetespib Showed Activity in KRAS-Mutant NSCLC as Monotherapy and in Combinations

January 10, 2012
Summary Toggle Synta Pharmaceuticals Prices Public Offering of Common Stock

January 06, 2012
Summary Toggle Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 05, 2012
Summary Toggle Ganetespib Potently Inhibits Multiple Signaling Pathways Active in Breast Cancer

December 12, 2011
Summary Toggle Ganetespib Shows Clinical Activity in HER2+ and Triple Negative Metastatic Breast Cancer

December 08, 2011
Summary Toggle Synta Announces Publication of Ganetespib Results in Molecular Cancer Therapeutics

December 06, 2011
Summary Toggle Synta Presents Results Showing Elesclomol Selectivity in Targeting Cancer Cell Metabolism

November 16, 2011
Summary Toggle Synta Presents Results on Ganetespib and Hsp90 Inhibitor Class at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference

November 15, 2011
Summary Toggle Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells to Chemoradiotherapy

November 10, 2011
Summary Toggle Synta to Present at the Lazard Capital Markets Annual Healthcare Conference

November 08, 2011
Summary Toggle Synta Provides Clinical Update and Reports Third-Quarter 2011 Financial Results

November 03, 2011
Summary Toggle Synta to Host Third-Quarter 2011 Conference Call on November 3

October 20, 2011
Summary Toggle Synta Announces Presentation of Results of Ganetespib Study in Combination with Docetaxel in Solid Tumors

September 26, 2011
Summary Toggle Synta to be Showcased in Congress as One of 13 Innovative Companies Seeking More Competitive American Business Environment

September 08, 2011
Summary Toggle Synta to Present at the Rodman & Renshaw Annual Global Investment Conference

September 06, 2011
Summary Toggle Synta Pharmaceuticals Provides Clinical Update and Reports Second-Quarter 2011 Financial Results

August 04, 2011
Summary Toggle Synta to Present at the Canaccord Genuity Annual Growth Conference

August 03, 2011
Summary Toggle Synta Pharmaceuticals to Host Second-Quarter 2011 Conference Call on August 4

July 21, 2011
Summary Toggle Synta Announces First Patient Treated in the GALAXY Trial a Phase 2b/3 Trial for Ganetespib in Advanced 2nd-line Non-small Cell Lung Cancer

July 20, 2011
Summary Toggle Synta Announces Presentation of Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results at IASLC 14th World Conference on Lung Cancer

July 07, 2011
Summary Toggle Synta Announces Presentation of Small Cell Lung Cancer Results at IASLC 14th World Conference on Lung Cancer

July 06, 2011
Summary Toggle Synta Announces Presentation of Additional Ganetespib Results at ASCO

June 06, 2011
Summary Toggle Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results Show Encouraging Single Agent Clinical Activity

June 04, 2011
Summary Toggle Synta to Present at the Jefferies 2011 Global Healthcare Conference

June 02, 2011
Summary Toggle Synta Announces Publication of Results Showing Ganetespib (STA-9090) Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling

May 26, 2011
Summary Toggle Synta Announces Ganetespib Clinical Data Presentations at the 2011 American Society for Clinical Oncology (ASCO) Annual Meeting

May 18, 2011
Summary Toggle Synta Announces Clinical Program Updates and First Quarter 2011 Financial Results

May 05, 2011
Summary Toggle Synta to Host First-Quarter 2011 Conference Call on May 5

April 21, 2011
Summary Toggle Synta Pharmaceuticals Announces $35 Million Registered Direct Offering of Common Stock

April 15, 2011
Summary Toggle Synta to Present at the Future Leaders in the Biotech Industry Conference

April 07, 2011
Summary Toggle Synta Announces Ganetespib Results at AACR - Inhibition of Multiple Oncogenes and Resistance Mechanisms Leads to Potent Activity in NSCLC and Strong Enhancement of Radiation Therapy

April 04, 2011
Summary Toggle Synta Announces Results Presented at AACR Further Elucidate Mechanism by Which Elesclomol Targets Cancer Cell Metabolism

April 04, 2011
Summary Toggle Synta to Host Investigator Panel Session on New Clinical Opportunities for Hsp90 Inhibition in Oncology

March 21, 2011
Summary Toggle Synta Announces Poster Presentations at the American Association for Cancer Research Annual Meeting

March 16, 2011
Summary Toggle Synta Announces Clinical Program Updates and 2010 Financial Results

March 11, 2011
Summary Toggle Synta to Present at the Barclays Capital Global Healthcare Conference

March 09, 2011
Summary Toggle Synta to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference

March 07, 2011
Summary Toggle Synta Announces Phase 2b/3 Trial for Ganetespib (STA-9090) in Advanced 2nd-line Non-small Cell Lung Cancer

February 26, 2011
Summary Toggle Synta Announces Encouraging Preliminary Results for Ganetespib (STA-9090) in Phase 2 Non-small Cell Lung Cancer Trial

February 26, 2011
Summary Toggle Synta to Host Fourth-Quarter and Year-End 2010 Conference Call on March 11, 2011

February 22, 2011
Summary Toggle Synta to Participate in Panel Titled Targeting Key Pathways in Cancer at the RBC Capital Markets Healthcare Conference

February 22, 2011
Summary Toggle Synta CEO, Safi Bahcall to Speak on Economic Panel at The Atlantic's Live Digital Town Hall on Wednesday, February 9

February 08, 2011
Summary Toggle Synta Announces First Patient Treated in Phase 1 Trial of Elesclomol in Acute Myeloid Leukemia

February 08, 2011
Summary Toggle Synta Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

February 07, 2011
Summary Toggle Synta Pharmaceuticals Announces Ganetespib (STA-9090) Non-small Cell Lung Cancer Phase 2 Interim Results to be Presented at the Upcoming IASLC 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting

January 27, 2011
Summary Toggle Multiple Myeloma Research Foundation (MMRF) and Synta Pharmaceuticals Enter into Joint Collaboration to Accelerate Drug Development for Myeloma Patients

January 12, 2011
Summary Toggle Synta Presents Encouraging Results for STA-9090 in Hematologic Cancers at ASH

December 07, 2010
Summary Toggle Synta Announces New Senior Hires in Clinical, Business Development, and Commercial Functions

December 01, 2010
Summary Toggle Synta Announces STA-9584 (Vascular Disrupting Agent) Recommended for $1M in DoD Funding for Study in Advanced Prostate Cancer

November 18, 2010
Summary Toggle Synta Pharmaceuticals Reports Sale of $5 Million in Common Stock to Member of Synta Board of Directors

November 11, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference

November 09, 2010
Summary Toggle Synta Pharmaceuticals Reports Third-Quarter 2010 Financial Results and Clinical Update

November 04, 2010
Summary Toggle Synta Announces Gynecologic Oncology Group (GOG) to Initiate Phase 2 Clinical Trial of Elesclomol for the Treatment of Ovarian Cancer

November 01, 2010
Summary Toggle Synta Pharmaceuticals to Host Third Quarter 2010 Conference Call on November 4, 2010

October 21, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Newsmakers in Biotechnology Conference

October 18, 2010
Summary Toggle Synta Pharmaceuticals Appoints Donald Kufe, M.D. to Board of Directors

September 30, 2010
Summary Toggle Synta Announces Expansion of Phase 2 Trial for STA-9090 in Non-Small Cell Lung Cancer Based on Encouraging Clinical Activity

September 13, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Robert W. Baird 2010 Health Care Conference

September 08, 2010
Summary Toggle Synta Announces First Patient Treated in Clinical Trial of STA-9090 in Combination with Docetaxel in Solid Tumors

August 24, 2010
Summary Toggle Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update

August 09, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

August 05, 2010
Summary Toggle Synta Announces STA-9090 Results Published in Journal "Blood" Demonstrating Potent In Vitro and In Vivo Activity in AML

July 27, 2010
Summary Toggle Synta Pharmaceuticals to Host Second-Quarter 2010 Conference Call on August 9, 2010

July 26, 2010
Summary Toggle Synta Announces Encouraging STA-9090 Clinical Results Presented at ASCO

June 07, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Jefferies Global Life Sciences Conference

June 03, 2010
Summary Toggle Synta Announces Clinical Data Presentations at ASCO

May 24, 2010
Summary Toggle Synta Announces Positive Results in Phase 2 NSCLC Trial for STA-9090 Support Advancing Trial to Second Stage

May 24, 2010
Summary Toggle Synta Pharmaceuticals Reports First Quarter 2010 Financial Results

May 04, 2010
Summary Toggle Synta Pharmaceuticals to Host First-Quarter 2010 Conference Call on May 4, 2010

April 22, 2010
Summary Toggle Synta Presents Results at AACR Supporting Correlative Markers for Elesclomol Activity

April 20, 2010
Summary Toggle Synta Presents STA-9090 Results at AACR Including Synergy with Avastin(R), Tarceva(R), and Taxanes; Downregulation of HIF-1a; Inhibition of JAK/STAT

April 19, 2010
Summary Toggle Synta Announces Poster Presentations at the American Association for Cancer Research Annual Meeting

April 07, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference

March 16, 2010
Summary Toggle Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results

March 11, 2010
Summary Toggle Synta Pharmaceuticals to Present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference

March 10, 2010
Summary Toggle Synta Announces Elesclomol Clinical Development to Resume

March 02, 2010
Summary Toggle Synta Presents STA-9090 NSCLC data at the IASLC10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting

February 26, 2010
Summary Toggle Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2009 Conference Call on March 11, 2010

February 25, 2010
Summary Toggle Synta Pharmaceuticals to Participate in Panel Titled New Targets in Cancer Therapy at the RBC Capital Markets Healthcare Conference

February 23, 2010
Summary Toggle Synta Announces STA-9090 ResultsDemonstrating Potent in vitro and in vivo Activity in AML

February 08, 2010
Summary Toggle Synta Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

February 01, 2010
Summary Toggle Synta Pharmaceuticals Sells Additional $3.75 Million of Common Stock

January 19, 2010
Summary Toggle Synta Presents Results at AACR-IASLC Demonstrating Potent and Synergistic Activity of STA-9090 in NSCLC Cell Lines Including Mutated EGFR, HER2, and KRAS

January 12, 2010
Summary Toggle Synta Pharmaceuticals Prices $25 Million Public Offering of Common Stock

January 08, 2010
Summary Toggle Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 07, 2010
Summary Toggle Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec® and Sutent®

December 23, 2009
Summary Toggle Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Non-Small Cell Lung Cancer

December 17, 2009
Summary Toggle Synta Pharmaceuticals Announces Encouraging Results for Elesclomol in AML In Vitro and Patient Ex-Vivo Studies Presented at ASH

December 07, 2009
Summary Toggle Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090

November 18, 2009
Summary Toggle Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

November 18, 2009
Summary Toggle Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference

November 11, 2009
Summary Toggle Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results

November 04, 2009
Summary Toggle Synta Pharmaceuticals to Host Third-Quarter 2009 Conference Call on November 4, 2009

October 22, 2009
Summary Toggle Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRY(SM) Data Presented at Melanoma XIII

October 12, 2009
Summary Toggle Synta Pharmaceuticals Initiates Fourth Trial of STA-9090, a Novel Synthetic Small Molecule Hsp90 Inhibitor

September 29, 2009
Summary Toggle Synta Pharmaceuticals to Present at the R.W. Baird Healthcare Conference

September 03, 2009
Summary Toggle Synta Pharmaceuticals Reports Second Quarter 2009 Financial Results

August 04, 2009
Summary Toggle Synta Pharmaceuticals to Host Second-Quarter 2009Conference Call on August 4, 2009

July 23, 2009
Summary Toggle Synta Pharmaceuticals Names Vojo Vukovic, M.D., Ph.D. Senior Vice President and Chief Medical Officer

June 19, 2009
Summary Toggle Synta and GSK End Elesclomol Collaboration Agreement

June 15, 2009
Summary Toggle Synta Pharmaceuticals Announces Presentation of Preliminary Results of Phase 3 SYMMETRY Trial of Elesclomol in Metastatic Melanoma at ASCO 2009

May 30, 2009
Summary Toggle Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 14, 2009
Summary Toggle Synta Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

May 11, 2009
Summary Toggle Synta Pharmaceuticals Reports First Quarter 2009 Financial Results

May 07, 2009
Summary Toggle Synta Pharmaceuticals to Host First-Quarter 2009 Conference Call on May 7, 2009

April 23, 2009
Summary Toggle Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva(R))-resistant Lung Cancer Models

April 21, 2009
Summary Toggle Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results

March 26, 2009
Summary Toggle Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2008 Conference Call on March 26, 2009

March 19, 2009
Summary Toggle Synta Pharmaceuticals Initiates Phase 1/2 Clinical Trial of STA-9090 in Hematologic Malignancies

March 17, 2009
Summary Toggle Synta Restructures Organization to Focus on New Priorities

March 13, 2009
Summary Toggle Synta Postpones Release of 2008 Year-End Financial Statements and Conference Call

March 11, 2009
Summary Toggle Synta Suspends Elesclomol SYMMETRYSM Trial in Metastatic Melanoma

February 26, 2009
Summary Toggle Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2008 Conference Call on March 12, 2009

February 26, 2009
Summary Toggle Synta Earns $10 Million from GlaxoSmithKline for Achieving Elesclomol Milestone

February 17, 2009
Summary Toggle Synta Pharmaceuticals to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference

February 11, 2009
Summary Toggle Synta Pharmaceuticals Announces First Patient Treated in Elesclomol Monotherapy Solid Tumor Clinical Study

February 10, 2009
Summary Toggle Synta Pharmaceuticals Names Dr. Vojo Vukovic, Vice President, Clinical Research

February 09, 2009
Summary Toggle Synta Completes Enrollment of the Phase 3 SYMMETRYSM Trial of Elesclomol in Stage IV Metastatic Melanoma

February 02, 2009
Summary Toggle Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2009

January 29, 2009
Summary Toggle Synta and Roche Form Discovery, Development, and Commercialization Alliance in Inflammation

January 07, 2009
Summary Toggle Synta Announces Continuation of the SYMMETRYSM Trial Based on Evaluation of Independent Data Monitoring Committee

December 18, 2008
Summary Toggle Synta Earns $15 Million from GlaxoSmithKline for Achieving Elesclomol Milestones

December 12, 2008
Summary Toggle Synta Pharmaceuticals to Participate in the RBC Capital Markets Healthcare Conference

December 03, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Piper Jaffray Annual Health Care Conference

November 25, 2008
Summary Toggle Synta Pharmaceuticals Announces First Patient Treated in Phase 1/2 Clinical Trial of Elesclomol in Prostate Cancer

November 20, 2008
Summary Toggle Synta Pharmaceuticals Reports Third Quarter 2008 Financial Results

November 13, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Conference

November 12, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference

November 03, 2008
Summary Toggle Synta Pharmaceuticals to Host Third-Quarter 2008 Conference Call on November 13, 2008

October 30, 2008
Summary Toggle Synta Earns $25 Million from GlaxoSmithKline for Achieving Elesclomol Milestones

October 14, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference

September 30, 2008
Summary Toggle Elesclomol Two-Year Survival and Integrated Safety Data Presented at the 33rd Congress of the European Society for Medical Oncology

September 15, 2008
Summary Toggle Synta Pharmaceuticals to Present at the UBS Global Life Sciences Conference

September 11, 2008
Summary Toggle Synta Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference

August 28, 2008
Summary Toggle Synta Announces Publication of Elesclomol Mechanism of Action Results in AACR Journal Molecular Cancer Therapeutics

August 22, 2008
Summary Toggle Synta Pharmaceuticals Reports Second Quarter 2008 Financial Results

August 07, 2008
Summary Toggle Synta Pharmaceuticals to Host Second-Quarter 2008 Conference Call on August 7, 2008

July 29, 2008
Summary Toggle Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer

July 14, 2008
Summary Toggle Synta Pharmaceuticals Corp.'s CEO Safi Bahcall Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner in New England

June 27, 2008
Summary Toggle Synta Pharmaceuticals to Present at the 4th Annual Collins Stewart Growth Conference

June 26, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference

June 05, 2008
Summary Toggle Synta Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference

May 21, 2008
Summary Toggle Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

May 20, 2008
Summary Toggle Synta Pharmaceuticals Reports First Quarter 2008 Financial Results

May 14, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

May 12, 2008
Summary Toggle Synta Pharmaceuticals Added to NASDAQ Biotechnology Index

May 12, 2008
Summary Toggle Synta Pharmaceuticals to Host First-Quarter 2008 Conference Call on May 14, 2008

May 09, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Deutsche Bank Securities 33rd Annual Health Care Conference

April 28, 2008
Summary Toggle Synta Pharmaceuticals to Present at the 15th Annual Future Leaders in the Biotech Industry Investment Conference

March 20, 2008
Summary Toggle Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

March 20, 2008
Summary Toggle Synta Pharmaceuticals to Host Analyst Event on Oxidative Stress Induction: A Novel Mechanism to Treat Cancer

March 12, 2008
Summary Toggle Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2007 Conference Call on March 20, 2008

March 06, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference

March 04, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference

March 04, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Susquehanna Financial Group SIGnificant Options in Healthcare Conference

February 26, 2008
Summary Toggle Synta Pharmaceuticals to Present at the ROTH Capital Partners 20th Annual OC Growth Stock Conference

February 13, 2008
Summary Toggle Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2008

January 31, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

January 29, 2008
Summary Toggle Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA

January 28, 2008
Summary Toggle Synta Pharmaceuticals Initiates Second Phase 1 Clinical Trial of STA-9090, A Novel Hsp90 Inhibitor

January 17, 2008
Summary Toggle Synta Pharmaceuticals to Present at the Wachovia 2008 Healthcare Conference

January 17, 2008
Summary Toggle Synta Receives $80 Million Upfront Payment from GlaxoSmithKline

December 05, 2007
Summary Toggle Synta Pharmaceuticals to Participate in the 2007 RBC Capital Markets Healthcare Conference

December 03, 2007
Summary Toggle Synta Pharmaceuticals to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference

November 14, 2007
Summary Toggle Synta Pharmaceuticals Reports Third-Quarter 2007 Financial Results

November 13, 2007
Summary Toggle Synta Reaches Agreement on Special Protocol Assessment and Initiates SYMMETRY Trial - a Pivotal Phase 3 Clinical Trial of Elesclomol in Metastatic Melanoma

November 12, 2007
Summary Toggle Synta Pharmaceuticals Initiates Phase 1 Clinical Trial of STA-9090, a Novel Hsp90 Inhibitor

November 08, 2007
Summary Toggle Synta Pharmaceuticals to Present at the 9th Annual MASS Opportunities Investment Conference

November 05, 2007
Summary Toggle Synta Pharmaceuticals to Host Third-Quarter Conference Call on November 13, 2007

November 05, 2007
Summary Toggle Synta Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

October 26, 2007
Summary Toggle Synta Presents New Data on Elesclomol (Formerly STA-4783) at AACR-NCI-EORTC International Conference

October 25, 2007
Summary Toggle GlaxoSmithKline and Synta Pharmaceuticals Announce Development and Commercialization Collaboration for STA-4783 in Oncology

October 10, 2007
Summary Toggle Synta to Present at European Conference on Clinical Oncology

September 18, 2007
Summary Toggle STA-4783 Data to be Presented at the First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology

August 31, 2007
Summary Toggle Synta Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference

August 27, 2007
Summary Toggle Synta Pharmaceuticals Reports Second Quarter 2007 Financial Results

August 06, 2007
Summary Toggle Synta Pharmaceuticals to Host Conference Call Today

June 05, 2007
Summary Toggle Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival

June 05, 2007
Summary Toggle Synta Pharmaceuticals to Present at the Bear Stearns Boston Biotech Confab Conference

May 31, 2007
Summary Toggle Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting

May 23, 2007
Summary Toggle Synta Pharmaceuticals Reports First Quarter 2007 Financial Results

May 07, 2007
Summary Toggle Synta Pharmaceuticals to Present at Acumen/BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference

April 26, 2007
Summary Toggle Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team

April 12, 2007
Summary Toggle Synta Pharmaceuticals Reports 2006 Fourth Quarter and Year-end Financial Results

March 28, 2007
Summary Toggle Synta Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference on March 29, 2007

March 27, 2007
Summary Toggle Synta Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference on March 21

March 13, 2007
Summary Toggle Synta Pharmaceuticals to Present at BIO CEO & Investor Conference February 12

February 08, 2007
Summary Toggle Synta Pharmaceuticals Corp. Announces Pricing of Its Initial Public Offering

February 06, 2007
Summary Toggle Synta Pharmaceuticals Corp. Announces Additions to Senior Management Team

January 23, 2007
Summary Toggle Synta Pharmaceuticals Corp. Files for Initial Public Offering

November 22, 2006
Summary Toggle Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma

November 15, 2006
Summary Toggle Synta Pharmaceuticals Announces Phase 2 Trial Data Showing STA-4783 Doubles Median Progression-Free Survival in Metastatic Melanoma

September 11, 2006
Summary Toggle Synta Pharmaceuticals to Present at Bear Stearns Conference and International Melanoma Congress

September 06, 2006
Summary Toggle Synta Pharmaceuticals Completes $40 Million Financing

July 11, 2006
Summary Toggle Synta Pharmaceuticals Initiates Phase 2 Clinical Trials in Rheumatoid Arthritis and CVID for First Oral Inhibitor of IL-12 and IL-23

May 24, 2006
Summary Toggle Synta Pharmaceuticals Announces Additions to Senior Management Team

May 11, 2006
Summary Toggle Synta Pharmaceuticals to Present at the Biocentry/Thomson "Future Leaders in the Biotech Industry" Conference

March 29, 2006
Summary Toggle Synta Pharmaceuticals to Present at BIO CEO Conference

February 09, 2006
Summary Toggle Synta Pharmaceuticals to Focus 2006 Development on its Oral IL-12 / IL-23 Inhibitor for Crohn's Disease and Rheumatoid Arthritis

December 23, 2005
Summary Toggle Judah Folkman, M.D. Joins the Board of Directors of Synta Pharmaceuticals

September 21, 2005
Summary Toggle Synta Pharmaceuticals Initiates Phase 2b Trial of First and Only Oral IL-12 and IL-23 Inhibitor in Crohn's Disease

September 14, 2005
Summary Toggle Synta Pharmaceuticals Presents Phase 2a Data at DDW for STA-5326 in Patients with Crohn's Disease

May 18, 2005
Summary Toggle Synta Pharmaceuticals Presents Preliminary Data at ASCO for STA-4783 in Patients with Non-Small Cell Lung Cancer and Soft Tissue Sarcoma

May 17, 2005
Summary Toggle Synta Pharmaceuticals Postpones Initial Public Offering

May 03, 2005
Summary Toggle Synta Pharmaceuticals Announces Key Senior Additions to Business and Scientific Teams

April 08, 2005
Summary Toggle Synta Pharmaceuticals Corp. Files for Initial Public Offering

January 18, 2005
Summary Toggle Synta Pharmaceuticals to Present at the Lazard Life Sciences Conference

November 24, 2004
Summary Toggle Synta Pharmaceuticals Announces Closing of $80 Million Round D Financing

November 22, 2004
Summary Toggle Synta Pharmaceuticals Strengthens Management Team with New Scientific and Business Appointments

October 15, 2004
Summary Toggle Synta Pharmaceuticals Appoints Industry Leader William S. Reardon to Board of Directors

September 24, 2004
Summary Toggle Synta Pharmaceuticals to Present at the UBS Global Life Sciences Conference

September 20, 2004
Summary Toggle Synta Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference

September 02, 2004
Summary Toggle Synta Pharmaceuticals Corp. named among top 15 Biotech Companies of 2004 by FierceBiotech

July 28, 2004
Summary Toggle Synta Pharmaceuticals Appoints Christopher J. Logothetis, M.D., Mace L. Rothenberg, M.D., and Daniel D. Von Hoff, M.D., F.A.C.P. to Oncology Advisory Board

June 25, 2004
Summary Toggle Synta Pharmaceuticals Appoints John A. McCarthy, Jr. as Senior Vice President Corporate Development and Chief Financial Officer, and Jeremy G. Chadwick, Ph.D. as Vice President, Program Management

June 04, 2004
Summary Toggle Synta Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Senior Vice President and Chief Medical Officer

March 09, 2004
Summary Toggle Synta Appoints Sir James W. Black, FRS, Judah Folkman, M.D., and Bruce Zetter, Ph.D. to its Scientific Advisory Board

March 02, 2004
Summary Toggle Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2004

February 20, 2004
Summary Toggle Synta Pharmaceuticals Announces Closing of $50 Million Round C Financing

January 14, 2004
Summary Toggle Synta Pharmaceuticals Appoints Pharmaceutical Industry Veteran Robert N. Wilson to Board of Directors

June 24, 2003
Summary Toggle Synta Pharmaceuticals Announces Closing of $75.3 million Round-B Financing - Largest Private Biopharmaceutical Financing in Past 12 Months

March 28, 2003

©2020 Madrigal Pharmaceuticals, Inc. All rights reserved.

- About Us
- Our Approach
- News Room
- Investors
- Contact Us
- Legal
- Privacy
- Cookies

Madrigal Pharmaceuticals
200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428

Madrigal Clinical Trials

Website Developed by Alan Leff Associates, Inc.